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The serotonin (5-HT) type 7 receptor is expressed throughout the CNS including the
cortex and hippocampus. We have previously demonstrated that the application of
5-HT7 receptor agonists to primary hippocampal neurons and SH-SY5Y cells increases
platelet-derived growth factor (PDGF) receptor expression and promotes neuroprotection
against N-methyl-D-aspartate-(NMDA)-induced toxicity. The tropomyosin-related kinase
B (TrkB) receptor is one of the receptors for brain-derived neurotrophic factor (BDNF)
and is associated with neurodevelopmental and neuroprotective effects. Application
of LP 12 to primary cerebral cortical cultures, SH-SY5Y cells, as well as the retinal
ganglion cell line, RGC-5, increased both the expression of full length TrkB as well as
its basal phosphorylation state at tyrosine 816. The increase in TrkB expression and
phosphorylation was observed as early as 30min after 5-HT7 receptor activation. In
addition to full-length TrkB, kinase domain-deficient forms may be expressed and act as
dominant-negative proteins toward the full length receptor. We have identified distinct
patterns of TrkB isoform expression across our cell lines and cortical cultures. Although
TrkB receptor expression is regulated by cyclic AMP and Gαs-coupled GPCRs in several
systems, we demonstrate that, depending on the model system, pathways downstream
of both Gαs and Gα12 are involved in the regulation of TrkB expression by 5-HT7
receptors. Given the number of psychiatric and degenerative diseases associated with
TrkB/BDNF deficiency and the current interest in developing 5-HT7 receptor ligands as
pharmaceuticals, identifying signaling relationships between these two receptors will aid
in our understanding of the potential therapeutic effects of 5-HT7 receptor ligands.
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INTRODUCTION
Neurotrophins, or neurotrophic factors, include nerve growth
factor (NGF), brain derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) (Skaper,
2012). One of the receptors for BDNF is the tropomyosin-related
kinase B (TrkB) receptor (Schecterson and Bothwell, 2010). TrkB
receptors are transmembrane receptor tyrosine kinases (RTKs)
found in dendritic spines, axons and neuronal cell bodies. There
are three TrkB isoforms, full-length TrkB (TrkB-FL), TrkB-Shc,
and TrkB-T1, that all have the same extracellular ligand-binding
domain and transmembrane domain, however, the T-Shc and
TrkB-T1 receptors are truncated and lack tyrosine kinase activity
found in TrkB-FL (Fenner, 2012). Both TrkB-T1 and TrkB-T-Shc
receptors are thought to modulate TrkB-FL activity by forming
Abbreviations: 5-HT, serotonin; BDNF, brain-derived neurotrophic factor; cyclic
AMP, cyclic adenosine mono-phosphate; GPCR, G protein-coupled receptor;
PDGF, platelet-derived growth factor; pLTF, phrenic long-term facilitation; PMF,
phrenic motor facilitation; RGC, retinal ganglion cell; RTK, receptor tyrosine
kinase; TrkB, tropomyosin-related kinase B.
heterodimers with TrkB-FL receptors as well as by competing for
and sequestering BDNF (Fenner, 2012; Gomes et al., 2012; Wong
and Garner, 2012). TrkB-FL receptors can be phosphorylated at
specific tyrosine residues including tyrosine 816 (Y816), the site
for activating phospholipase Cγ (Huang and Reichardt, 2003).
Recent work suggests that the relative number of TrkB isoforms
expressed (e.g., TrkB-FL vs. TrkB-T1) is key for the neuropro-
tective signaling of BDNF. For example, increases in TrkB-T1
(via increased transcription, not as a degradation product of the
full-length receptor) decrease TrkB-FL activity after excitotoxicity
(Gomes et al., 2012).
A common theme in the regulation of TrkB signaling involves
the secondmessenger cyclic AMP. BDNF-induced TrkB phospho-
rylation is regulated by cyclic AMP signaling in hippocampal neu-
rons (Ji et al., 2005) and TrkB cell surface expression is regulated
by cyclic AMP in retinal ganglion cells (RGCs) (Meyer-Franke
et al., 1998). TrkB expression is also regulated by cyclic AMP sig-
naling in several other systems (Heo et al., 2013). For example, the
activation of the Gαs-coupled adenosine 2A receptors increases
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TrkB expression in the spinal cord (Golder et al., 2008). A2A
receptors also promote an increased expression and release of the
BDNF in rat cortical cultures (Jeon et al., 2011). In addition to
changes in protein expression, GPCRs can increase RTK activa-
tion via a process called transactivation: adenosine 2A receptors
and the Gαs-coupled dopamine D1 receptor are both able to
transactivate TrkB (Lee et al., 2002; Wiese et al., 2007; Iwakura
et al., 2008). 5-HT7 receptors are also reported to couple to Gαs
(Bard et al., 1993; Lovenberg et al., 1993; Ruat et al., 1993) as well
as Gα12 (Kvachnina et al., 2005).
TrkB-FL has been linked to neuroprotective effects after CNS
insults by excitotoxicity, amyloid-β, and the HIV protein gp120
(Almeida et al., 2005; Nosheny et al., 2005; Kitiyanant et al.,
2012) and changes in TrkB-FL are associated with neurodegener-
ative diseases (Longo et al., 2007; Zuccato and Cattaneo, 2009).
In schizophrenia, as our understanding of the condition has
shifted to viewing the disease as a neurodevelopmental illness,
there has been an increased focus on neurotrophic factor sig-
naling in its pathophysiology (Kalkman, 2009) and there is a
strong association with BDNF with valine at position 66 (instead
of methionine) and the illness (Rybakowski, 2008). Decreases
in BDNF signaling are also associated with glaucoma and reti-
nal degeneration (Gupta et al., 2014). A direct physiological link
between 5-HT7 receptors and TrkB expression has been observed
in a model of phrenic long-term facilitation (pLTF), a form of
plasticity in the respiratory system that occurs as a response to
hypoxia (Mitchell and Johnson, 2003). This centrally-mediated
form of potentiation is associated with changes in 5-HT, BDNF,
and TrkB signaling (Fuller et al., 2001; Baker-Herman et al.,
2004). Recently, Hoffman and Mitchell demonstrated that spinal
5-HT7 receptor activation by the 5-HT7 receptor agonist, AS-
19, was able to induce phrenic motor facilitation (PMF) that was
dependent on new TrkB synthesis and activation (Hoffman and
Mitchell, 2011). Initially these authors proposed a model whereby
5-HT7 receptor agonists might promote pLTF after hypoxia; how-
ever subsequent findings suggested the opposite: 5-HT7 agonists
countered pLTF and antagonists (SB-269970) facilitated pLTF
in conjunction with 5-HT2 receptor activation (Hoffman and
Mitchell, 2013).
We have recently reported that long-term (24 h) application
of 5-HT7 agonists (5-carboxamidotryptamine (5-CT) and LP
12) increases the expression of the platelet-derived growth fac-
tor (PDGF) β receptor in a PKA-dependent manner (Vasefi
et al., 2012) and this increase in PDGF receptor expression
was sufficient to protect primary hippocampal neurons against
NMDA-induced excitotoxicity (Vasefi et al., 2013). Given that
TrkB expression is regulated by several other Gαs-coupled recep-
tors, we examined the ability of 5-HT7 agonists and antagonists
to regulate TrkB receptor isoform expression and phosphory-
lation in primary mouse cerebral cortical cultures, the human
neuroblastoma-derived SH-SY5Y cell line, and the RGC line 5
(RGC-5).
MATERIALS AND METHODS
REAGENTS AND ANTIBODIES
LP12 [4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-
piperazinehexanamide hydrochloride] and H89 were purchased
from Sigma-Aldrich (St. Louis, MO). SB 258719 ((R)-3,N-Di-
methyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzene
sulfonamide) and SB 269970 (R-3-(2-(2-(4-methylpiperidin-
1-yl)ethyl)-pyrrolidine-1-sulfonyl)-phenol were purchased
from Tocris (Ellisville, MO, USA). Rhosin was purchased from
Calbiochem (Billerica, MA). Antibodies against TrkB (catalog
#sc-8316, used at a dilution of 1:500) and β-actin (catalog
#sc-81178, used at a dilution of 1:500) were purchased from
Santa Cruz (Santa Cruz, CA). The TrkB-Y816 antibody (catalog
#ab75173, used at a dilution of 1:500) was purchased from
Abcam (Toronto, ON). The secondary antibodies [horseradish
peroxidase (HRP) enzyme-conjugated mouse polyclonal IgG
and HRP enzyme conjugated rabbit polyclonal IgG] were both
purchased from Thermo Fisher (Pittsburgh, PA).
PRIMARY CEREBRAL CORTICAL CULTURES
E17 to E19 mouse embryos were removed from pregnant CD-1
mice (Harlan, Indianapolis, IN) and transferred to chilled dis-
section media (15mL HEPES buffer in 500mL HBSS with 2.5 g
glucose (0.6%), 10 g sucrose (2%), pH 7.4, final osmolality 320–
335). The cortex was removed, separated, and trypsinized with
0.25% trypsin for 20min at 37◦C. Cells were then plated on poly-
d-lysine-coated culture dished and grown at 37◦C in a humidified
atmosphere of 95% air and 5% CO2. Cells were plated with plat-
ing media (DMEM, supplemented with 10% fetal bovine serum,
10% horse serum) for the first 2–4 h until attached and then
with feeding media consisting of Neurobasal medium and B-27
supplement (Life Technologies, Burlington, ON) without serum.
Drug treatments were performed 7–10 days after plating the
cells. Media was changed twice per week. To stop the overgrowth
of non-neuronal cells, a mitotic inhibitor (81μM 5-fluoro-2′-
deoxyuridine and 200μMuridine added to media) was added for
24 h once cells reached confluency.
CELL CULTURE
SH-SY5Y cells were grown on DMEM with Ham’s F12 in a 1:1
ratio (Thermo Fisher), 10% fetal bovine serum and 1% peni-
cillin/streptomycin. Media was changed every 2–3 days and cells
were kept at 37◦C and 5% CO2. Cells were serum and antibiotic
deprived 24 h prior to drug treatment to prevent any interactions
with growth factors. The RGC-5 cell line was grown onDulbecco’s
Modified Eagle Medium (DMEM) with low glucose (Thermo
Fisher), 10% horse serum and 1% penicillin/streptomycin. Media
was changed every 2 days and cells were kept at 37◦C and 5%CO2.
WESTERN BLOT
After drug treatment, cells were washed with phosphate-buffered
saline (PBS) and lysed in chilled lysis buffer (20mM Tris-HCl at
pH 7.5, 150mMNaCl, 1mMEDTA, 1mMEGTA, 30mM sodium
pyrophosphate, 1mM β-glycerophosphate, 1mM sodium ortho-
vanadate, and 1% Triton X-100; supplemented with Halt Protease
and Phosphatase Inhibitor (Thermo, Fisher, Markham, Ontario)
prior to use). Cells were scraped, sheared using 26 gage nee-
dles, and centrifuged at 14,000 × g for 20min at 4◦C and the
supernatant was collected. Protein concentrations were deter-
mined using a BCA protein assay protocol (Thermo Fisher).
Homogenates were subjected to SDS-PAGE and proteins were
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transferred to nitrocellulose membranes, blocked with 5% non-
fat dry milk in Tris-buffered saline and 0.1% Tween-20 for 1 h
at room temperature or overnight at 4◦C, and incubated in
primary antibodies for 1 h at room temperature or overnight
at 4◦C. Membranes were washed three times in Tris-buffered
saline with 0.1% Tween-20, incubated with HRP-conjugated sec-
ondary antibodies for 1 h at room temperature, washed again, and
bound antibodies were visualized by enhanced chemilumines-
cence using Luminata Crescendo substrate (Millipore, Etobicoke,
Ontario). Images of Western blots were taken on a Kodak
4000MM Pro Imaging Station, and densitometric analyses were
performed using Kodak Molecular Imaging software. Protein
bands were then identified by their molecular weights: TrkB-
FL and TrkB-Y816 at 145 kDa, TrkB T1 at 95 kDa, TrkB T-Shc
at 105 kDa, and bands were normalized to the loading control,
β-actin.
STATISTICAL ANALYSIS
Mean protein expression/phosphorylation and standard errors
were calculated usingMicrosoft Excel. GraphPad Prism® software
was used for graphing and for analyzing statistical significance
using a One-Way ANOVA with a Dunnett’s or Bonferroni’s post-
test. Significance level was set to α = 0.05.
ANIMALS
All animal experiments were performed in agreement with the
guidelines of the policies on the Use of Animals at the University
of Waterloo under animal utilization project proposal (AUPP)
#13-24 in accordance with standards of the Canadian Council on
Animal Care.
RESULTS
24 h ACTIVATION OF 5-HT7 RECEPTORS INCREASE TrkB EXPRESSION
Based on our previous findings that 24 h treatment of SH-SY5Y
cells and primary cultures with 5-HT7 receptor agonists increased
the expression of the PDGFβ receptor, we incubated primary
mouse cerebral cortical cultures with the 5-HT7 receptor agonist
LP 12 (300 nM) in the absence or presence of the 5-HT7 receptor
antagonist SB 258719 (1μM). LP 12 increased the expression of
full-length TrkB (TrkB-FL) and this was blocked by the antago-
nist (Figure 1A). The same treatments resulted in similar effects
in SH-SY5Y cells (Figure 1B). In both cell types, LP 12-induced
increases in TrkB were also blocked using the inverse 5-HT7
receptor agonist, SB 269970 (data not shown). The concentration
of 300 nM LP 12 was chosen based on our previous work on the
regulation of PDGFβ receptor expression in similar model sys-
tems (Vasefi et al., 2013). Preliminary experiments in SH-SY5Y
cells demonstrated that the application of concentrations higher
than 300 nM resulted in sub-maximal increases in TrkB receptor
expression (data not shown). In addition to TrkB-FL, we detected
the expression of TrkB-T1 at 95 kDa and TrkB-T-Shc at 105 kDa.
In both cortical neurons and SH-SY5Y cells, LP 12 treatment also
resulted in an increase in TrkB-T-Shc and T1 by approximately
1.5 fold however these changes were not significant. In RGC-5
cells, 24 h LP 12 treatment significantly increased TrkB-FL and
TrkB-T-Shc and there was a trend toward an even larger increase
in TrkB-T1 but the result was much more variable and not sta-
tistically significant (Figure 1C). In all three model systems, the
phosphorylation of Y816 on the full length TrkB receptor (a phos-
phorylation site associated with increased TrkB receptor activity;
Huang and Reichardt, 2003) was significantly increased over base-
line (1.40 ± 0.15, n = 7 in cortical neurons, 1.34 ± 0.12, n = 7 in
SH-SY5Y cells, and 1.31 ± 0.12, n = 7 in RGC-5 cells).
2 h ACTIVATION OF 5-HT7 RECEPTORS INCREASES TrkB EXPRESSION
We then investigated whether a shorter incubation of cortical
neurons, SH-SY5Y or RGC-5 cells with LP 12 would result in sim-
ilar changes in TrkB expression and phosphorylation. In cortical
cultures, 2 h treatment with LP 12 failed to alter TrkB recep-
tor expression (Figure 2A). Similarly, 2 h incubation of ex vivo
hippocampal slices resulted in variable changes in TrkB expres-
sion, however this treatment significantly increased TrkB Y816
phosphorylation (1.24 ± 0.06 fold vs. vehicle, n = 3, p < 0.05,
unpaired t-test, data not shown). In SH-SY5Y and RGC-5 cells,
LP 12 treatment increased the expression of TrkB-FL but differ-
entially increased TrkB-T1 in SH-SY5Y cells and T-Shc in RGC-5
cells (Figures 2B,C). A significant increase in Y816 phosphoryla-
tion was observed in RGC-5 cells (1.43 ± 0.09, n = 4) but not
SH-SY5Y cells (1.22 ± 0.08, n = 6) and cortical neurons (1.59 ±
0.39, n = 5) after 2 h LP 12 treatment.
BOTH Gαs AND Gα12 PATHWAYS ARE INVOLVED IN 5-HT7
RECEPTOR-INDUCED TrkB EXPRESSION
There is evidence that 5-HT7 receptors couple to both Gαs and
Gα12 (Bard et al., 1993; Lovenberg et al., 1993; Ruat et al., 1993;
Kvachnina et al., 2005). To determine which G protein pathway(s)
leads to an increase in TrkB expression we incubated SH-SY5Y
and RGC-5 cells with the cyclic AMP-dependent protein kinase
(PKA) inhibitor, H89, or the RhoA inhibitor, rhosin. In SH-
SY5Y, pretreatment with H89 (30min, 10μM) attenuated the
increase in TrkB (FL) by LP 12 (Figure 3A). However, the RhoA
inhibitor, rhosin (30min, 30μM) also inhibited the increase in
TrkB expression (Figure 3B). In contrast, rhosin, but not H89,
blocked LP 12-induced increases in TrkB expression in RGC-
5 cells (Figures 3C,D). Taken together these results suggest that
multiple G protein pathways may be involved in promoting TrkB
expression downstream of the 5-HT7 receptor and that different
pathways may be involved in different systems.
LP 12 TREATMENT RESULTS IN DIFFERENT PATTERNS OF TrkB
ISOFORM EXPRESSION IN SH-SY5Y AND RGC-5 CELLS
We performed a time course experiment with LP 12 in the two
models, SH-SY5Y and RGC-5 cells, that displayed differences in
TrkB expression at 2 h. Both cell types were treated for 0.5, 1, 1.5,
2, 3, or 4 h with 300 nM LP 12 and changes in the three TrkB
receptor isoforms were measured. As shown in Figures 4A,B, we
observed very rapid changes in TrkB isoform expression as well as
different patterns of TrkB isoform expression. In SH-SY5Y cells,
changes were observed with all isoforms (however only changes
in TrkB-FL at 1.5 and 2 h and TrkB-T1 at 2 h were significant,
Figure 4A). In RGC-5 cells, changes in TrkB-FL were observed
at earlier time points and LP 12 treatment did not significantly
affect the expression of the other isoforms (Figure 4B). Note that
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FIGURE 1 | 5-HT7 receptor activation increases TrkB receptor
expression in several model systems. (A) Primary mouse cerebral
cortical cultures were treated for 24 h with vehicle, 300 nM LP 12, 1μM
SB 258719, or both. The expression of TrkB-FL was normalized to β-actin
and compared to the untreated sample (vehicle). ∗∗p < 0.01 compared to
vehicle, #, p < 0.05 compared to LP 12, n = 5, ANOVA analysis with
Bonferroni’s post-test. Representative western blots are shown for all TrkB
isoforms and β-actin. Note that for “A” only the order of samples in the
blot is different from the graph. (B) SH-SY5Y cells were treated as in “A.”
∗p < 0.05, n = 10. (C) RGC-5 cells were treated with vehicle or 300 nM LP
12 for 24 h. The expression of TrkB-FL (145 kDa), TrkB-T-Shc (105 kDa) and
TrkB-T1 (95 kDa) were normalized to β-actin and compared to vehicle.
∗p < 0.05, n = 7–9, one-sample t-test. Representative blots are shown for
all TrkB isoforms and β-actin.
unlike Figure 2C, in these five time-course experiments we did
not observe changes in TrkB-T-Shc levels.
5-HT7 RECEPTOR-INDUCED TrkB RECEPTOR TRANSACTIVATION
In addition to being activated by its ligand, BDNF, TrkB recep-
tors can be transactivated after activation of GPCRs including
adenosine 2A and dopamine D1 receptors (Lee et al., 2002;
Wiese et al., 2007; Iwakura et al., 2008). To determine if 5-HT7
receptors are able to acutely transactivate TrkB receptors we per-
formed a time-course similar to that described in Figure 4 but
with the addition of a 15min time point. Interestingly, in SH-
SY5Y cells, TrkB receptor transactivation was very brief (15min)
whereas in RGC-5 cells, the transactivation time course was
more typical of that reported by others; the increase in TrkB
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FIGURE 2 | Short-term incubation with LP 12 differentially alters TrkB
isoform expression. (A) Cortical cultures were treated as in Figure 1A for 2 h.
The expression of TrkB-FL was normalized to β-actin and compared to the
untreated sample (vehicle). n = 5. Representative blots are shown for each TrkB
isoform and β-actin. (B) SH-SY5Y cells were treated for 2 h with 300 nM LP 12.
Expression of TrkB-FL, T-Shc, and T1 were normalized to β-actin and compared
to vehicle. ∗p < 0.05, n = 3, one-sample t-test. Representative blots are shown
for all TrkB isoforms and β-actin. (C)RGC-5 cellswere treated as in “B.” n = 3–6.
receptor phosphorylation after LP 12 treatment lasted up to 2 h
(Figure 5).
DISCUSSION
In cortical cultures, SH-SY5Y cells, and RGC-5 cells, 24 h LP 12
treatment increased the expression of full length TrkB expres-
sion and its basal phosphorylation at Y816 and although the
expression of T-Shc and T1 were also elevated over baseline
in all models, only TrkB-T-Shc was significantly increased in
RGC-5 cells. Over a shorter time period, differences in 5-HT7
receptor regulation of TrkB receptor isoforms were observed. In
SH-SY5Y cells, 2 h LP 12 treatment increased TrkB-FL and TrkB-
T1 isoforms, whereas TrkB-FL and TrkB-T-Shc were increased in
RGC-5 cells. TrkB-T1 and T-Shc are generally ascribed dominant-
negative activity toward full length TrkB (Gomes et al., 2012;
Wong and Garner, 2012) as well as regulating TrkB cell surface
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FIGURE 3 | Different pathways are involved in 5-HT7 receptor-induced
increases in TrkB expression in SH-SY5Y cells and RGC-5 cells. SH-SY5Y
cells were pre-treated with 10μM H89 (A) or 30μM rhosin (B) for 30min
prior to the addition of 300 nM LP 12 for 2 additional h. RGC-5 cells were
similarly treated with H89 (C) or rhosin (D) prior to incubation with LP 12. The
expression of TrkB-FL was normalized to β-actin and compared to the
untreated sample (vehicle). ∗p < 0.05 compared to vehicle, n = 4 (A–C),
n = 5 (D), ANOVA analysis with Dunnett’s post-test.
expression (Haapasalo et al., 2002). Thus, signaling pathways
that regulate TrkB expression and/or cell surface localization will
produce a complex net effect of changes in TrkB-FL and the dom-
inant negative forms. In neurons, this complexity is compounded
by the relative localization of TrkB forms at synapses, cell bodies,
etc. Although we observed changes in TrkB isoform expression
in cortical cultures at 24 h, we did not see reliable changes over
shorter time periods. This may be due to the reduced sensitivity
of measuring changes in mixed neuronal cultures or the relatively
lower expression of 5-HT7 receptors in the cortex compared to
other brain regions (Horisawa et al., 2013).
Based on our previous work (Vasefi et al., 2012), and the
literature identifying Gαs-coupled receptors and cyclic AMP
pathways in regulating TrkB receptor expression (Ji et al., 2005;
Heo et al., 2013), we predicted that 5-HT7 receptor activation
would increase TrkB receptor levels via the Gαs-cyclic AMP-
PKA pathway. However, 5-HT7 receptors are also reported to
couple to Gα12 and Rho GTPase pathways, specifically the acti-
vation of RhoA and cdc42 (Kvachnina et al., 2005). As both of
these monomeric G proteins are involved in cell growth in neu-
rons, the Ponimaskin group recently demonstrated the involve-
ment of 5-HT7 receptor/Gα12 in dendritic growth and synaptic
activity/plasticity (Kobe et al., 2012). In our model systems, the
changes in TrkB expression involved PKA and RhoA signaling
pathways, or both, depending on the cell line. Many of the effects
of 5-HT7 receptor signaling observed by Kobe et al. were in devel-
oping neurons after a 4 days treatment with the 5-HT7 (and
5-HT1a) agonist, 5-CT (Kobe et al., 2012). We observed changes
in TrkB expression after 24 h as well as over shorter time periods.
Interestingly, the TrkB receptor and BDNF signaling are inti-
mately involved withmany of the processes Kobe et al. observed in
their systems (Kobe et al., 2012): see recent reviews on the involve-
ment of TrkB/BDNF in dendritic spine formation (Bennett and
Lagopoulos, 2014), synaptogenesis (Luikart and Parada, 2006),
and synaptic plasticity (Lu et al., 2014).
The term transactivation is used to describe acute and usually
very brief (5–15min) GPCR-induced activation of RTKs that does
not involve changes in RTK protein expression. This may occur
through entirely intracellular signal transduction pathways, as in
the case of 5-HT-induced transactivation of the PDGFβ and TrkB
receptor in SH-SY5Y cells (Kruk et al., 2013). Anothermechanism
involves a GPCR-induced metalloproteinase-dependent shedding
of growth factor ligand (such as EGF) to activate its RTK (Wetzker
and Bohmer, 2003). TrkB receptor transactivation often differs
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FIGURE 4 | Time course for the effects of LP 12 on TrkB isoform
expression. SH-SY5Y cells (A) or RGC-5 cells (B) were incubated for
30–240min with 300 nM LP 12. Expression of TrkB-FL, T-Shc, and T1 were
normalized to β-actin and compared to vehicle. ∗p < 0.05, n = 3–4 (SH-SY5Y),
n = 5–6 (RGC-5 cells), ANOVA with Dunnett’s post-test. Representative blots
are shown for all TrkB isoforms and β-actin.
FIGURE 5 | 5-HT7 receptor transactivation of the TrkB receptor. SH-SY5Y
cells (black bars, upper three blots) or RGC-5 cells (gray bars, lower three
blots) were incubated for 15–240min with 300 nM LP 12. Phosphorylation of
the TrkB was measured using an anti-TrkB-phospho-Y816 antibody and
compared to vehicle. ∗p < 0.05, n = 4 (SH-SY5Y), n = 5 (RGC-5 cells),
ANOVA analysis with Dunnett’s post-test. The data from each cell line were
collected independently thus the statistical test for each cell line were
analyzed independently, however the data are presented together for
comparison purposes. Representative blots are shown for phosphor-Y816,
TrkB isoforms, and β-actin.
from the transactivation of other RTKs in that it typically mani-
fests as a longer-lasting increase in receptor phosphorylation (Lee
et al., 2002). Interestingly, we observed three distinct patterns of
TrkB receptor transactivation by LP 12 in the three systems we
investigated. Transactivation of TrkB was not reliably observed in
cortical cultures. In SH-SY5Y, we observed a brief (15min) trans-
activation that quickly returned to baseline, typical of many other
RTK transactivation pathways. In RGC-5 we observed a transacti-
vation typical of the TrkB receptor: one that was delayed in onset
but much longer lasting. It remains to be determined what fac-
tors contribute to TrkB transactivation differing kinetically from
the transactivation of other RTKs.
Given the interest in targeting growth and neurotrophic fac-
tor signaling pathways in CNS disease, an attempt to develop
direct small molecule modulators for RTKs are ongoing, and in
fact the TrkB receptor has been at the forefront of this avenue of
investigation (Longo et al., 2007; Webster and Pirrung, 2008). An
alternative approach to modulating RTKs in the CNS is to iden-
tify GPCRs linked to RTK signaling and expression. For 5-HT7
receptors, we have demonstrated such an approach in vitro: the
5-HT7 receptor ligand, LP 12, increases PDGFβ receptor expres-
sion in hippocampal neurons to provide neuroprotection against
excitotoxicity (Vasefi et al., 2013). The development of selective
5-HT7 receptors able to cross the blood-brain barrier (Monti
et al., 2014) will allow us to test the ability of 5-HT7 receptor lig-
ands to modify RTK activity in situ in the CNS. Glaucoma is a
family of eye diseases that results in visual field loss and even-
tual blindness (Weinreb et al., 2014). A reduction in BDNF is
thought to contribute to the complex mechanisms of RGC death
in glaucoma (Gupta et al., 2014). In rat, application of exoge-
nous BDNF to the retina through intravitreal injection resulted
in a promotion of RGC survival (Ko et al., 2001) thus there is
extensive interest in delivering exogenous BDNF to the retina
Frontiers in Behavioral Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 391 | 7
Samarajeewa et al. 5-HT7 receptors increase TrkB expression
as a glaucoma therapy. This has resulted in several approaches
directed toward the delivery of neuroprotective genes to the retina
in a less-invasive manner (Park et al., 2012; Alqawlaq et al., 2014).
An alternative approach would be to exploit the 5-HT7 receptor’s
ability to promote TrkB expression and phosphorylation in situ
in the retina. We began to explore this possibility in vitro using
the RGC-5 cell line. Unfortunately, the integrity of the RGC-5
cell line has recently been compromised given investigations that
revealed that the cell line does not express ubiquitous markers of
RGCs and that its origin is from mouse and not rat as previously
reported (Van Bergen et al., 2009). Nevertheless, 5-HT7-TrkB
receptor linkages have been demonstrated here in two cell lines as
well as in cortical cultures, and is likely present in the spinal cord
(Hoffman and Mitchell, 2011, 2013). Therefore, further investi-
gation of the possibility of 5-HT7 receptor-induced regulation in
TrkB signaling in the retina and throughout the CNS is warranted.
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